Drug intelligence / Profile preview

Aloe arborescens

Development stage
Unknown
Administration
Topical, Oral, Ophthalmic
01

Overview

Aloe arborescens, also known as Candelabra or Krantz aloe, is a plant species with a long history of use in traditional medicine. It is being investigated for a wide range of therapeutic applications due to its complex chemical composition, which includes bioactive compounds like anthraquinones (e.g., aloin, emodin), chromones, saponins, and polysaccharides. [39731399, 37002349] Numerous preclinical and clinical studies have explored its anticancer properties. A standardized glycosidic fraction from the plant has been shown to suppress hepatocellular carcinoma in animal models by modulating the expression of genes involved in tumor invasion (MMP9, TIMP1) and signaling pathways related to inflammation and cell proliferation (NF-κB, Ki-67, TGFβ1). [39731399] Furthermore, a randomized clinical study in patients with metastatic solid tumors found that combining *Aloe arborescens* with chemotherapy significantly increased tumor regression rates and 3-year survival compared to chemotherapy alone. [3, 4] Extracellular vesicles from the plant containing photosensitizing anthraquinones have also demonstrated phototoxic effects against melanoma cells, suggesting potential for photodynamic therapy. [39594594] Beyond oncology, *Aloe arborescens* has demonstrated anti-inflammatory, immunomodulatory, antioxidant, and antimicrobial activities. [36840217, 34439997, 5] An aqueous extract is a component of a product approved in some European countries for treating upper respiratory tract infections in children. [7, 8, 12] It is also being studied for inflammatory bowel disease, with derivatives shown to attenuate colitis in mouse models. [37367827] Other applications include topical treatment for nipple complications in breastfeeding mothers, protection against alcoholic liver injury, and use as a dietary supplement in dairy cows to improve metabolic health. [35255973, 36788475, 36239181]

Other names
Candelabra aloeKrantz aloe
02

Targets

TIMP1 (Metalloproteinase inhibitor 1)Sucrase-IsomaltaseAcetylcholinesteraseRELA (Nuclear Factor Kappa B Subunit p65)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)ButyrylcholinesteraseTGFB1 (Transforming growth factor Beta-1 proprotein)MMP9 (Matrix metalloproteinase-9)HMOX1 (Heme oxygenase 1)HYAL (Hyaluronidase family (HYAL))

Beyond the preview

Go deeper on Aloe arborescens.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aloe arborescens.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call